trending Market Intelligence /marketintelligence/en/news-insights/trending/veSVFnJQSPm3wp8En1Xm0Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Correvio's irregular heartbeat drug Brinavess rejected by US FDA

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Correvio's irregular heartbeat drug Brinavess rejected by US FDA

Correvio Pharma Corp. said the U.S. Food and Drug Administration rejected its irregular heartbeat drug Brinavess, in line with the recommendations of one of its advisory committees.

The Vancouver, British Columbia-based company said that while the regulator found the medicine to be effective, it raised concerns related to its safety. Brinavess, or vernakalant, is approved in 41 countries outside the U.S. for atrial fibrillation, or an irregular heartbeat, in adults.

The U.S. FDA's cardiovascular and renal drugs advisory committee recently voted against the approval of Brinavess for similar reasons. While the FDA is not required to follow the committee's vote, the recommendation is taken into consideration.

The regulator has asked Correvio to conduct another clinical study assessing patient safety if the company plans to pursue approval of the medicine again. This is the second time the agency has rejected the drug.

After the FDA advisory committee rejection, Correvio said it was exploring strategic alternatives for the business and was planning to reduce its operating costs outside its core commercial business.